RhumbLine Advisers’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

RhumbLine Advisers’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Buy	77,845 +3,260	+4%	+$10K	﹤0.01%	3037
2025 Q4	$266K	Sell	74,585 -8,794	-11%	-$32.6K	﹤0.01%	3037
2025 Q3	$291K	Sell	83,379 -1,852	-2%	-$6.35K	﹤0.01%	3020
2025 Q2	$175K	Buy	+85,231	New	+$213K	﹤0.01%	3303
2024 Q3	–	Sell	-2,175	Closed	-$1K	–	4327
2024 Q2	$1K	Hold	2,175	–	–	﹤0.01%	4244
2024 Q1	$3.44K	Hold	2,175	–	–	﹤0.01%	4032
2023 Q4	$4.44K	Hold	2,175	–	–	﹤0.01%	4004
2023 Q3	$3.04K	Sell	2,175 -10,037	-82%	-$10.4K	﹤0.01%	4061
2023 Q2	$6.72K	Sell	12,212 -26,388	-68%	-$14K	﹤0.01%	4032
2023 Q1	$26K	Buy	38,600 +1,818	+5%	+$2.32K	﹤0.01%	2930
2022 Q4	$61K	Buy	36,782 +1,154	+3%	+$3.24K	﹤0.01%	2945
2022 Q3	$165K	Buy	35,628 +13,141	+58%	+$77.3K	﹤0.01%	2932
2022 Q2	$114K	Buy	+22,487	New	+$164K	﹤0.01%	3023

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's STLN Position: Q1 2026 in Review

RhumbLine Advisers increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 4.4% in Q1 2026, buying an estimated $10K and bringing the position to 77,845 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3037.

RhumbLine Advisers first reported a position in STLN in Q2 2022 and has held it in 13 quarters since. The position peaked at $291K in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

RhumbLine Advisers held 77,845 shares of Starling Oncology Institute, Inc. Common Stock worth $239K as of Q1 2026.
RhumbLine Advisers bought 3,260 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $10K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3037 holding.
RhumbLine Advisers first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 13 quarters since.
RhumbLine Advisers's Starling Oncology Institute, Inc. Common Stock position peaked at $291K in Q3 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.